Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Strata Critical Medical's Debt-to-EBITDA or its related term are showing as below:
SRTA'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.43 Med: -0.21 Max: -0.03
Current: -0.43
During the past 7 years, the highest Debt-to-EBITDA Ratio of Strata Critical Medical was -0.03. The lowest was -0.43. And the median was -0.21.
SRTA's Debt-to-EBITDA is ranked worse than 100% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs SRTA: -0.43
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Strata Critical Medical Debt-to-EBITDA Related Terms
Strata Critical Medical Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Strata Critical Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Critical Medical Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Strata Critical Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Strata Critical Medical (SRTA) has a Debt-to-EBITDA of 0.34 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Strata Critical Medical. According to the industry distribution chart, Strata Critical Medical ranks #999999 out of 476 companies in the Healthcare Providers & Services industry.
Is Strata Critical Medical's Debt-to-EBITDA too high?
Strata Critical Medical's current Debt-to-EBITDA is 0.34. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. Strata Critical Medical's value of 0.34 is 84.5% below this industry median. Based on the distribution chart, Strata Critical Medical ranks #999999 out of 476 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Strata Critical Medical has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's Debt-to-EBITDA compare to CCRN and CYH?
According to the Healthcare Providers & Services industry distribution chart, Strata Critical Medical ranks #999999 out of 476 companies for Debt-to-EBITDA. This places Strata Critical Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. Strata Critical Medical's value of 0.34 is 84.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Critical Medical's current Debt-to-EBITDA of 0.34 is 84.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Strata Critical Medical. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Critical Medical's current Debt-to-EBITDA is 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.48, compared to a current price of $5.58 — trading 24.4% above its estimated fair value. The current Debt-to-EBITDA is 0.34 and 84.5% below the Healthcare Providers & Services industry median of 2.20. Strata Critical Medical's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current Debt-to-EBITDA is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Critical Medical (SRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued.
The current stock price of $5.58 is trading 24.4% above its estimated GF Value™ of $4.48.
GuruFocus considers Strata Critical Medical to be Modestly Overvalued.
Key valuation signals for SRTA:
Debt-to-EBITDA: 0.34
GF Value™: $4.48 vs. price of $5.58 (24.4% above fair value)
Industry Position: 84.5% below the Healthcare Providers & Services median (#999999 of 476)
No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
74GF Score
Get the complete analysis for SRTA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTA has been successfully added to your 
